The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2005-06

AUTHORS

Katia Boven, Scott Stryker, John Knight, Adrian Thomas, Marc van Regenmortel, David M Kemeny, David Power, Jerome Rossert, Nicole Casadevall

ABSTRACT

BACKGROUND: The incidence of pure red cell aplasia (PRCA) in chronic kidney disease patients treated with epoetins increased substantially in 1998, was shown to be antibody mediated, and was associated predominantly with subcutaneous administration of Eprex. A technical investigation identified organic compounds leached from uncoated rubber stoppers in prefilled syringes containing polysorbate 80 as the most probable cause of the increased immunogenicity. METHODS: This study investigated whether the incidence of PRCA was higher for exposure to the product form containing leachates than for leachate-free product forms. Antibody-mediated PRCA cases were classified according to indication, product form, and route of administration. Exposure estimates were obtained by country, indication, route of administration, and product form. RESULTS: For 2001 to 2003, the PRCA incidence rate for patients with subcutaneous exposure to Eprex in prefilled syringes with polysorbate 80 and uncoated rubber stoppers (leachates present) was 4.61/10,000 patient years (95% CI 3.88-5.43) versus 0.26/10,000 patient years (95% CI 0.007-1.44) for syringes with coated stoppers (leachates absent). The rate difference was 4.35/10,000 patient years (95% CI 3.44-5.26; P < 0.0001); the rate ratio was 17 (95% CI 3.14-707). A substantial rate difference remained in sensitivity analyses that adjusted for exposure to multiple product forms. CONCLUSION: The epidemiologic data, together with the chemical and immunologic data, support the hypothesis that leachates from uncoated rubber syringe stoppers caused the increased incidence of PRCA associated with Eprex. Currently, all Eprex prefilled syringes contain fluoro-resin coated stoppers, which has contributed to decreased incidence of PRCA with continued surveillance. More... »

PAGES

2346-2353

References to SciGraph publications

  • 1990. Pure Red Cell Aplasia in APLASTIC ANEMIA AND OTHER BONE MARROW FAILURE SYNDROMES
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1111/j.1523-1755.2005.00340.x

    DOI

    http://dx.doi.org/10.1111/j.1523-1755.2005.00340.x

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1019837931

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/15882278


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Chemistry, Pharmaceutical", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Erythropoietin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Incidence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Polysorbates", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Recombinant Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Red-Cell Aplasia, Pure", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Syringes", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Janssen (United States)", 
              "id": "https://www.grid.ac/institutes/grid.497530.c", 
              "name": [
                "Johnson and Johnson, Pharmaceutical Research and Development, L.L.C, Raritan, New Jersey, USA."
              ], 
              "type": "Organization"
            }, 
            "familyName": "Boven", 
            "givenName": "Katia", 
            "id": "sg:person.01204727113.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204727113.47"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Stryker", 
            "givenName": "Scott", 
            "type": "Person"
          }, 
          {
            "familyName": "Knight", 
            "givenName": "John", 
            "id": "sg:person.01247077410.69", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247077410.69"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Thomas", 
            "givenName": "Adrian", 
            "type": "Person"
          }, 
          {
            "familyName": "van Regenmortel", 
            "givenName": "Marc", 
            "type": "Person"
          }, 
          {
            "familyName": "Kemeny", 
            "givenName": "David M", 
            "id": "sg:person.01345274433.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345274433.00"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Power", 
            "givenName": "David", 
            "id": "sg:person.01050643265.26", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050643265.26"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Rossert", 
            "givenName": "Jerome", 
            "id": "sg:person.014715013334.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014715013334.05"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Casadevall", 
            "givenName": "Nicole", 
            "id": "sg:person.0611511710.41", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611511710.41"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1056/nejmoa011931", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003176759"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/ndt/gfg489", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003764365"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/ndt/gfg188", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004305419"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/ndt/17.suppl_5.42", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014299498"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejm199608153350717", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015497061"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/ndt/gfg182", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015569963"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/ndt/17.1.42", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015571012"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa040528", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024111810"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-1-4612-3254-4_16", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026824711", 
              "https://doi.org/10.1007/978-1-4612-3254-4_16"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/1531-8249(200011)48:5<706::aid-ana3>3.0.co;2-v", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044497354"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/01.asn.0000107561.59698.42", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1060319468"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/01.asn.0000107561.59698.42", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1060319468"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/01.asn.0000107561.59698.42", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1060319468"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1075207681", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1083101526", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2005-06", 
        "datePublishedReg": "2005-06-01", 
        "description": "BACKGROUND: The incidence of pure red cell aplasia (PRCA) in chronic kidney disease patients treated with epoetins increased substantially in 1998, was shown to be antibody mediated, and was associated predominantly with subcutaneous administration of Eprex. A technical investigation identified organic compounds leached from uncoated rubber stoppers in prefilled syringes containing polysorbate 80 as the most probable cause of the increased immunogenicity.\nMETHODS: This study investigated whether the incidence of PRCA was higher for exposure to the product form containing leachates than for leachate-free product forms. Antibody-mediated PRCA cases were classified according to indication, product form, and route of administration. Exposure estimates were obtained by country, indication, route of administration, and product form.\nRESULTS: For 2001 to 2003, the PRCA incidence rate for patients with subcutaneous exposure to Eprex in prefilled syringes with polysorbate 80 and uncoated rubber stoppers (leachates present) was 4.61/10,000 patient years (95% CI 3.88-5.43) versus 0.26/10,000 patient years (95% CI 0.007-1.44) for syringes with coated stoppers (leachates absent). The rate difference was 4.35/10,000 patient years (95% CI 3.44-5.26; P < 0.0001); the rate ratio was 17 (95% CI 3.14-707). A substantial rate difference remained in sensitivity analyses that adjusted for exposure to multiple product forms.\nCONCLUSION: The epidemiologic data, together with the chemical and immunologic data, support the hypothesis that leachates from uncoated rubber syringe stoppers caused the increased incidence of PRCA associated with Eprex. Currently, all Eprex prefilled syringes contain fluoro-resin coated stoppers, which has contributed to decreased incidence of PRCA with continued surveillance.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1111/j.1523-1755.2005.00340.x", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1015319", 
            "issn": [
              "0085-2538", 
              "1523-1755"
            ], 
            "name": "Kidney International", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "6", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "67"
          }
        ], 
        "name": "The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes", 
        "pagination": "2346-2353", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "5e84d0cf3b629921c3ca17e0eb19050430bc85c304290d0f6f76b28516d9ec7e"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "15882278"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "0323470"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1111/j.1523-1755.2005.00340.x"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1019837931"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1111/j.1523-1755.2005.00340.x", 
          "https://app.dimensions.ai/details/publication/pub.1019837931"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-10T18:08", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000424.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://www.nature.com/ki/journal/v67/n6/full/4495312a.html"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1111/j.1523-1755.2005.00340.x'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1111/j.1523-1755.2005.00340.x'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1111/j.1523-1755.2005.00340.x'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1111/j.1523-1755.2005.00340.x'


     

    This table displays all metadata directly associated to this object as RDF triples.

    184 TRIPLES      21 PREDICATES      50 URIs      29 LITERALS      17 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1111/j.1523-1755.2005.00340.x schema:about N0580c072b2d44e69a4fbf29d2b7ceb8a
    2 N10bbf50a450f427887de16191b943497
    3 N34efa82c9f5247639e9f1f333002ce37
    4 N8b28d86adeb042a791c13f40ee88d375
    5 Na2ecddaaa6394960bf5f0abbf16a0387
    6 Na399c72d684e43d993e7a57017120e1f
    7 Ncae5fac7efa7423688b030645e0a58f5
    8 Ncc9ff62fef7a421ab418c9a590ca8372
    9 anzsrc-for:11
    10 anzsrc-for:1103
    11 schema:author N3d55e809217c464c9fb2b7cda7475094
    12 schema:citation sg:pub.10.1007/978-1-4612-3254-4_16
    13 https://app.dimensions.ai/details/publication/pub.1075207681
    14 https://app.dimensions.ai/details/publication/pub.1083101526
    15 https://doi.org/10.1002/1531-8249(200011)48:5<706::aid-ana3>3.0.co;2-v
    16 https://doi.org/10.1056/nejm199608153350717
    17 https://doi.org/10.1056/nejmoa011931
    18 https://doi.org/10.1056/nejmoa040528
    19 https://doi.org/10.1093/ndt/17.1.42
    20 https://doi.org/10.1093/ndt/17.suppl_5.42
    21 https://doi.org/10.1093/ndt/gfg182
    22 https://doi.org/10.1093/ndt/gfg188
    23 https://doi.org/10.1093/ndt/gfg489
    24 https://doi.org/10.1097/01.asn.0000107561.59698.42
    25 schema:datePublished 2005-06
    26 schema:datePublishedReg 2005-06-01
    27 schema:description BACKGROUND: The incidence of pure red cell aplasia (PRCA) in chronic kidney disease patients treated with epoetins increased substantially in 1998, was shown to be antibody mediated, and was associated predominantly with subcutaneous administration of Eprex. A technical investigation identified organic compounds leached from uncoated rubber stoppers in prefilled syringes containing polysorbate 80 as the most probable cause of the increased immunogenicity. METHODS: This study investigated whether the incidence of PRCA was higher for exposure to the product form containing leachates than for leachate-free product forms. Antibody-mediated PRCA cases were classified according to indication, product form, and route of administration. Exposure estimates were obtained by country, indication, route of administration, and product form. RESULTS: For 2001 to 2003, the PRCA incidence rate for patients with subcutaneous exposure to Eprex in prefilled syringes with polysorbate 80 and uncoated rubber stoppers (leachates present) was 4.61/10,000 patient years (95% CI 3.88-5.43) versus 0.26/10,000 patient years (95% CI 0.007-1.44) for syringes with coated stoppers (leachates absent). The rate difference was 4.35/10,000 patient years (95% CI 3.44-5.26; P < 0.0001); the rate ratio was 17 (95% CI 3.14-707). A substantial rate difference remained in sensitivity analyses that adjusted for exposure to multiple product forms. CONCLUSION: The epidemiologic data, together with the chemical and immunologic data, support the hypothesis that leachates from uncoated rubber syringe stoppers caused the increased incidence of PRCA associated with Eprex. Currently, all Eprex prefilled syringes contain fluoro-resin coated stoppers, which has contributed to decreased incidence of PRCA with continued surveillance.
    28 schema:genre research_article
    29 schema:inLanguage en
    30 schema:isAccessibleForFree true
    31 schema:isPartOf N1c4dd6aa0f18444b9caa1964197b4173
    32 N75b809aa49c84e52a387075533d9d1b0
    33 sg:journal.1015319
    34 schema:name The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes
    35 schema:pagination 2346-2353
    36 schema:productId N1b4901f5d7f842159ca9946c8991a94d
    37 N4eb396ca709b4216be4bc0d86bb8388f
    38 N85e152a958d64bdc8ed091054248c937
    39 N960bba25976647299d039c19a34bfdc4
    40 Nbbdf313067574f1694aa709ebeaa928f
    41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019837931
    42 https://doi.org/10.1111/j.1523-1755.2005.00340.x
    43 schema:sdDatePublished 2019-04-10T18:08
    44 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    45 schema:sdPublisher Nf2c6c22b5daf45d9a29719536780406a
    46 schema:url http://www.nature.com/ki/journal/v67/n6/full/4495312a.html
    47 sgo:license sg:explorer/license/
    48 sgo:sdDataset articles
    49 rdf:type schema:ScholarlyArticle
    50 N0580c072b2d44e69a4fbf29d2b7ceb8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    51 schema:name Syringes
    52 rdf:type schema:DefinedTerm
    53 N10bbf50a450f427887de16191b943497 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    54 schema:name Chemistry, Pharmaceutical
    55 rdf:type schema:DefinedTerm
    56 N1b4901f5d7f842159ca9946c8991a94d schema:name nlm_unique_id
    57 schema:value 0323470
    58 rdf:type schema:PropertyValue
    59 N1c4dd6aa0f18444b9caa1964197b4173 schema:issueNumber 6
    60 rdf:type schema:PublicationIssue
    61 N34efa82c9f5247639e9f1f333002ce37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    62 schema:name Recombinant Proteins
    63 rdf:type schema:DefinedTerm
    64 N3bb0e6c5603742a0b5b8b0c0c17924b6 rdf:first Na4efea835ed949fea10dd74f9bee912c
    65 rdf:rest N84ee6085445646ce90f396424041235b
    66 N3d55e809217c464c9fb2b7cda7475094 rdf:first sg:person.01204727113.47
    67 rdf:rest N9e60145cd6954c4e881b83caedcc21e7
    68 N4e68a265c6274152b0edea22dc89c0dc rdf:first sg:person.01247077410.69
    69 rdf:rest N3bb0e6c5603742a0b5b8b0c0c17924b6
    70 N4eb396ca709b4216be4bc0d86bb8388f schema:name pubmed_id
    71 schema:value 15882278
    72 rdf:type schema:PropertyValue
    73 N5423c6cf64714d3eae41279b71442073 rdf:first sg:person.014715013334.05
    74 rdf:rest Na5edd83a112747e7acf9eac433fd1ccf
    75 N75b809aa49c84e52a387075533d9d1b0 schema:volumeNumber 67
    76 rdf:type schema:PublicationVolume
    77 N7b907bce7a644b8b911abed66e92d3ce rdf:first sg:person.01345274433.00
    78 rdf:rest Ncf996cc5be65472486244c5f930cc3ce
    79 N84ee6085445646ce90f396424041235b rdf:first Na67f7fddd3074aaa879c0c6ca13237c1
    80 rdf:rest N7b907bce7a644b8b911abed66e92d3ce
    81 N85e152a958d64bdc8ed091054248c937 schema:name dimensions_id
    82 schema:value pub.1019837931
    83 rdf:type schema:PropertyValue
    84 N8b28d86adeb042a791c13f40ee88d375 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    85 schema:name Humans
    86 rdf:type schema:DefinedTerm
    87 N960bba25976647299d039c19a34bfdc4 schema:name readcube_id
    88 schema:value 5e84d0cf3b629921c3ca17e0eb19050430bc85c304290d0f6f76b28516d9ec7e
    89 rdf:type schema:PropertyValue
    90 N9e60145cd6954c4e881b83caedcc21e7 rdf:first Naea0f1fc6947435a8e6463f170baee8d
    91 rdf:rest N4e68a265c6274152b0edea22dc89c0dc
    92 Na2ecddaaa6394960bf5f0abbf16a0387 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    93 schema:name Incidence
    94 rdf:type schema:DefinedTerm
    95 Na399c72d684e43d993e7a57017120e1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    96 schema:name Erythropoietin
    97 rdf:type schema:DefinedTerm
    98 Na4efea835ed949fea10dd74f9bee912c schema:familyName Thomas
    99 schema:givenName Adrian
    100 rdf:type schema:Person
    101 Na5edd83a112747e7acf9eac433fd1ccf rdf:first sg:person.0611511710.41
    102 rdf:rest rdf:nil
    103 Na67f7fddd3074aaa879c0c6ca13237c1 schema:familyName van Regenmortel
    104 schema:givenName Marc
    105 rdf:type schema:Person
    106 Naea0f1fc6947435a8e6463f170baee8d schema:familyName Stryker
    107 schema:givenName Scott
    108 rdf:type schema:Person
    109 Nbbdf313067574f1694aa709ebeaa928f schema:name doi
    110 schema:value 10.1111/j.1523-1755.2005.00340.x
    111 rdf:type schema:PropertyValue
    112 Ncae5fac7efa7423688b030645e0a58f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    113 schema:name Polysorbates
    114 rdf:type schema:DefinedTerm
    115 Ncc9ff62fef7a421ab418c9a590ca8372 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    116 schema:name Red-Cell Aplasia, Pure
    117 rdf:type schema:DefinedTerm
    118 Ncf996cc5be65472486244c5f930cc3ce rdf:first sg:person.01050643265.26
    119 rdf:rest N5423c6cf64714d3eae41279b71442073
    120 Nf2c6c22b5daf45d9a29719536780406a schema:name Springer Nature - SN SciGraph project
    121 rdf:type schema:Organization
    122 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    123 schema:name Medical and Health Sciences
    124 rdf:type schema:DefinedTerm
    125 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    126 schema:name Clinical Sciences
    127 rdf:type schema:DefinedTerm
    128 sg:journal.1015319 schema:issn 0085-2538
    129 1523-1755
    130 schema:name Kidney International
    131 rdf:type schema:Periodical
    132 sg:person.01050643265.26 schema:familyName Power
    133 schema:givenName David
    134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050643265.26
    135 rdf:type schema:Person
    136 sg:person.01204727113.47 schema:affiliation https://www.grid.ac/institutes/grid.497530.c
    137 schema:familyName Boven
    138 schema:givenName Katia
    139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204727113.47
    140 rdf:type schema:Person
    141 sg:person.01247077410.69 schema:familyName Knight
    142 schema:givenName John
    143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247077410.69
    144 rdf:type schema:Person
    145 sg:person.01345274433.00 schema:familyName Kemeny
    146 schema:givenName David M
    147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345274433.00
    148 rdf:type schema:Person
    149 sg:person.014715013334.05 schema:familyName Rossert
    150 schema:givenName Jerome
    151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014715013334.05
    152 rdf:type schema:Person
    153 sg:person.0611511710.41 schema:familyName Casadevall
    154 schema:givenName Nicole
    155 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611511710.41
    156 rdf:type schema:Person
    157 sg:pub.10.1007/978-1-4612-3254-4_16 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026824711
    158 https://doi.org/10.1007/978-1-4612-3254-4_16
    159 rdf:type schema:CreativeWork
    160 https://app.dimensions.ai/details/publication/pub.1075207681 schema:CreativeWork
    161 https://app.dimensions.ai/details/publication/pub.1083101526 schema:CreativeWork
    162 https://doi.org/10.1002/1531-8249(200011)48:5<706::aid-ana3>3.0.co;2-v schema:sameAs https://app.dimensions.ai/details/publication/pub.1044497354
    163 rdf:type schema:CreativeWork
    164 https://doi.org/10.1056/nejm199608153350717 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015497061
    165 rdf:type schema:CreativeWork
    166 https://doi.org/10.1056/nejmoa011931 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003176759
    167 rdf:type schema:CreativeWork
    168 https://doi.org/10.1056/nejmoa040528 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024111810
    169 rdf:type schema:CreativeWork
    170 https://doi.org/10.1093/ndt/17.1.42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015571012
    171 rdf:type schema:CreativeWork
    172 https://doi.org/10.1093/ndt/17.suppl_5.42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014299498
    173 rdf:type schema:CreativeWork
    174 https://doi.org/10.1093/ndt/gfg182 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015569963
    175 rdf:type schema:CreativeWork
    176 https://doi.org/10.1093/ndt/gfg188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004305419
    177 rdf:type schema:CreativeWork
    178 https://doi.org/10.1093/ndt/gfg489 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003764365
    179 rdf:type schema:CreativeWork
    180 https://doi.org/10.1097/01.asn.0000107561.59698.42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060319468
    181 rdf:type schema:CreativeWork
    182 https://www.grid.ac/institutes/grid.497530.c schema:alternateName Janssen (United States)
    183 schema:name Johnson and Johnson, Pharmaceutical Research and Development, L.L.C, Raritan, New Jersey, USA.
    184 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...